What question did this study set out to answer?

To evaluate the efficacy of novel antibody-drug conjugates targeting tumor-specific Tn-glycoforms of MUC1 and MUC4 in epithelial cancers.

April 5, 2026

Abstract 6923: Targeting tumor-specific Tn-glycoforms of MUC1 and MUC4 with first-in-class antibody-drug conjugates: Preclinical efficacy and translational potential of GO-M100B and GO-M400

Key Points

To evaluate the efficacy of novel antibody-drug conjugates targeting tumor-specific Tn-glycoforms of MUC1 and MUC4 in epithelial cancers.
Developed monoclonal antibodies recognizing Tn-glycoforms of MUC1 and MUC4.
Engineered site-specific antibody-drug conjugates (ADCs) using mc-vc-PAB-MMAE linker.
Tested ADCs in vitro on Tn-positive cell lines to assess cytotoxic effects.
Assessed in vivo efficacy in cell-derived and patient-derived xenograft models.
ADCs demonstrated potent selective cytotoxicity with sub-nanomolar IC50 values against Tn-positive cell lines.
Both GO-M100B and GO-M400 induced significant tumor regression in xenograft models.
No measurable activity was observed in Tn-negative or primary normal cell models.
Favorable pharmacokinetics and clean toxicology profiles were noted in animal studies.

Abstract

Abstract Aberrant O-glycosylation in epithelial cancers generates tumor-specific neoepitopes absent from normal tissues. GO Therapeutics has developed monoclonal antibodies that selectively recognize these Tn-glycoforms on mucins, including GO-M100B, targeting Tn-MUC1, and GO-M400, targeting Tn-MUC4. These antibodies bind aberrantly truncated O-glycans presented on mucin backbones with sub- to low-nanomolar affinity and exceptional site-specificity. These programs exemplify our “clean target” approach that exploits cancer-restricted glycoepitopes to enhance selectivity and therapeutic index. Structural and biochemical characterization revealed that M100B and M400 recognize proprietary glycopeptide neoepitopes unique to malignant epithelial cells, enabling precise tumor targeting. Immunohistochemistry confirmed broad reactivity across epithelial cancers. This includes breast, lung, ovarian, pancreatic, and gastrointestinal tumors. Negligible binding was seen to normal tissues. Both antibodies were engineered as site-specific antibody-drug conjugates (ADCs) using an mc-vc-PAB-MMAE linker to generate homogeneous DAR2 conjugates. These ADCs exhibited potent, selective cytotoxicity against Tn-positive cell lines, achieving sub-nanomolar IC50 values, while showing no measurable activity in Tn-negative or primary normal cell models. In vivo, M100B-vedotin and M400-vedotin induced marked tumor regression in both cell-derived (CDX) and patient-derived xenograft (PDX) models, with favorable pharmacokinetics and clean toxicology profiles in cynomolgus monkeys and mice. By targeting cancer-specific glycosylation patterns on mucins, M100B and M400 expand the therapeutic frontier of “clean target” oncology. These next-generation ADCs demonstrate exceptional tumor selectivity, strong preclinical efficacy, and favorable safety, supporting advancement into IND-enabling studies and clinical development for multiple epithelial malignancies. Citation Format: Nisha Shrestha, Aaron Christopher Groen, Boris Klebanov, Constantine Theodoropulos, Hans H. Wandall. Targeting tumor-specific Tn-glycoforms of MUC1 and MUC4 with first-in-class antibody-drug conjugates: Preclinical efficacy and translational potential of GO-M100B and GO-M400 abstract. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 6923.

KI fragen

Bookmark